| Jesse D Wilburn, DO | |
|
621 S Illinois Ave Ste 100, Mason City, IA 50401-5489 | |
| (641) 428-6900 | |
| (641) 428-6909 |
| Full Name | Jesse D Wilburn |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 6 Years |
| Location | 621 S Illinois Ave Ste 100, Mason City, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134610355 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | R-11202 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Springhill Medical Center | Mobile, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Inpatient Consultants Of Alabama, Inc | 6709983422 | 15 |
News Archive
While officials in Washington, D.C., grappled with delays and red tape, two professional virus hunters raced to make thousands of tests available to detect the deadly new coronavirus sweeping the globe, hoping to stem its spread in the U.S.
Sandia National Laboratories is seeking commercial partners to license or contribute to the continued development of a new lab-on-a-chip platform for high-throughput manipulation and interrogation of individual cells, one that enables quantitative analysis of cellular behaviors with unprecedented speed, resolution, sensitivity, and multiplexing.
People living with HIV who naturally produce broadly neutralizing antibodies (bNAbs) that may help suppress the virus have different immunological profiles than people who do not, researchers report.
Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.
By blocking the molecule's anchoring ability, researchers may be able to find a way to stave off the most common serious infection of the central nervous system and a major cause of childhood death and disability. The researchers' findings appear in the September 2005 issue of the Journal of Clinical Investigation.
› Verified 7 days ago
| Entity Name | Inpatient Consultants Of Alabama, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235238916 PECOS PAC ID: 6709983422 Enrollment ID: O20110805000011 |
News Archive
While officials in Washington, D.C., grappled with delays and red tape, two professional virus hunters raced to make thousands of tests available to detect the deadly new coronavirus sweeping the globe, hoping to stem its spread in the U.S.
Sandia National Laboratories is seeking commercial partners to license or contribute to the continued development of a new lab-on-a-chip platform for high-throughput manipulation and interrogation of individual cells, one that enables quantitative analysis of cellular behaviors with unprecedented speed, resolution, sensitivity, and multiplexing.
People living with HIV who naturally produce broadly neutralizing antibodies (bNAbs) that may help suppress the virus have different immunological profiles than people who do not, researchers report.
Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.
By blocking the molecule's anchoring ability, researchers may be able to find a way to stave off the most common serious infection of the central nervous system and a major cause of childhood death and disability. The researchers' findings appear in the September 2005 issue of the Journal of Clinical Investigation.
› Verified 7 days ago
| Entity Name | University Of South Alabama Health Care Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508392432 PECOS PAC ID: 4082986088 Enrollment ID: O20170825003180 |
News Archive
While officials in Washington, D.C., grappled with delays and red tape, two professional virus hunters raced to make thousands of tests available to detect the deadly new coronavirus sweeping the globe, hoping to stem its spread in the U.S.
Sandia National Laboratories is seeking commercial partners to license or contribute to the continued development of a new lab-on-a-chip platform for high-throughput manipulation and interrogation of individual cells, one that enables quantitative analysis of cellular behaviors with unprecedented speed, resolution, sensitivity, and multiplexing.
People living with HIV who naturally produce broadly neutralizing antibodies (bNAbs) that may help suppress the virus have different immunological profiles than people who do not, researchers report.
Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.
By blocking the molecule's anchoring ability, researchers may be able to find a way to stave off the most common serious infection of the central nervous system and a major cause of childhood death and disability. The researchers' findings appear in the September 2005 issue of the Journal of Clinical Investigation.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jesse D Wilburn, DO 621 S Illinois Ave Ste 103, Mason City, IA 50401-5489 Ph: (641) 428-3041 | Jesse D Wilburn, DO 621 S Illinois Ave Ste 100, Mason City, IA 50401-5489 Ph: (641) 428-6900 |
News Archive
While officials in Washington, D.C., grappled with delays and red tape, two professional virus hunters raced to make thousands of tests available to detect the deadly new coronavirus sweeping the globe, hoping to stem its spread in the U.S.
Sandia National Laboratories is seeking commercial partners to license or contribute to the continued development of a new lab-on-a-chip platform for high-throughput manipulation and interrogation of individual cells, one that enables quantitative analysis of cellular behaviors with unprecedented speed, resolution, sensitivity, and multiplexing.
People living with HIV who naturally produce broadly neutralizing antibodies (bNAbs) that may help suppress the virus have different immunological profiles than people who do not, researchers report.
Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.
By blocking the molecule's anchoring ability, researchers may be able to find a way to stave off the most common serious infection of the central nervous system and a major cause of childhood death and disability. The researchers' findings appear in the September 2005 issue of the Journal of Clinical Investigation.
› Verified 7 days ago
Burt Humburg, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 4th St Sw, Mason City, IA 50401 Phone: 641-428-7000 Fax: 641-428-6383 | |
Sumathy Nagraj Iyengar, M.D., Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 4th St Sw, Mercy Medical Center-hospitalist Dept, Mason City, IA 50401 Phone: 641-428-7000 | |
Mark C Johnson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 910 N Eisenhower Ave, Mason City, IA 50401 Phone: 641-428-7799 Fax: 641-428-5274 | |
Dr. Joseph Dean Mccracken, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 4th St Sw, Mason City, IA 50401 Phone: 641-428-6300 Fax: 641-428-6347 | |
Nathaniel Hitt, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 621 S Illinois Ave Ste 100, Mason City, IA 50401 Phone: 641-428-6900 Fax: 641-428-3909 | |
Dr. Byron T Beasley, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 S Crescent Dr, Mason City, IA 50401 Phone: 641-494-5300 Fax: 641-494-5329 | |
Radu Hagau, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 S Crescent Dr, Mason City, IA 50401 Phone: 641-494-5300 Fax: 641-494-5321 |